scholarly journals The platelet endothelial cell adhesion molecule PECAM1 is differentially expressed in non-small cell lung cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Cell Adhesion ◽  
Endothelial Cell ◽  
Small Cell Lung Cancer ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platelet Endothelial Cell Adhesion ◽  
Endothelial Cell Adhesion

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1, 2). We mined published microarray data (3, 4) to discover genes associated with NSCLC tumors. We identified significant differential expression of the platelet endothelial cell adhesion molecule PECAM1 (5) in primary tumors from patients with NSCLC. PECAM1 may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.

scholarly journals The endothelial cell adhesion molecule, ESAM, is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Cell Adhesion ◽  
Endothelial Cell ◽  
Small Cell Lung Cancer ◽  
Adhesion Molecule ◽  
Cell Lung Cancer ◽  
Cell Adhesion Molecule ◽  
Small Cell ◽  
Small Cell Lung ◽  
Endothelial Cell Adhesion

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding the endothelial cell adhesion molecule, ESAM, was among those whose expression was most different in human NSCLC tumors as compared to the lung. ESAM expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of ESAM in patient tumors was significantly associated with worse overall survival. ESAM may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

2009 ◽  
Vol 27 (35) ◽  
pp. 6006-6011 ◽  
Author(s):  
Leora Horn ◽  
Suzanne E. Dahlberg ◽  
Alan B. Sandler ◽  
Afshin Dowlati ◽  
Dennis F. Moore ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Adhesion ◽  
Growth Factor ◽  
Small Cell Lung Cancer ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Response Rate ◽  
Small Cell ◽  
Small Cell Lung ◽  
Extensive Stage

PurposeTo investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC).Patients and MethodsIn this phase II trial, 63 patients were treated with bevacizumab 15 mg/kg plus cisplatin 60 mg/m2and etoposide 120 mg/m2, which was followed by bevacizumab alone until death or disease progression occurred. The primary end point was the proportion of patients alive at 6 months without disease progression (ie, progression-free survival [PFS]). Secondary end points included overall survival (OS), objective response rate, and toxicity. Correlative studies were performed to explore the relationship between baseline and changes in plasma vascular endothelial growth factor (VEGF), soluble cell adhesion molecules (ie, vascular cell adhesion molecule [VCAM], intercellular cell adhesion molecule [ICAM], and E-selectin) and basic fibroblast growth factor and outcome.ResultsThe 6-month PFS was 30.2%, the median PFS was 4.7 months, and OS was 10.9 months. The response rate was 63.5%. The most common adverse event was neutropenia (57.8%). Only one patient had grade 3 pulmonary hemorrhage. Patients who had high baseline VCAM had a higher risk of progression or death compared with those who had low baseline VCAM levels. No relationships between outcome and any other biomarkers were seen.ConclusionThe addition of bevacizumab to cisplatin and etoposide in patients with ED-SCLC results in improved PFS and OS relative to historical controls who received this chemotherapy regimen without bevacizumab. This regimen appears to be well tolerated and has minimal increase in toxicities compared with chemotherapy alone. Baseline VCAM levels predicted survival, but no other relationships among treatment, biomarkers, and outcome were identified.

Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer

2000 ◽  
Vol 14 (3) ◽  
pp. 173-179 ◽  
Author(s):  
Masako N. Hosono ◽  
Makoto Hosono ◽  
Anil K. Mishra ◽  
Alain Faivre-Chauvet ◽  
Emmanuel Gautherot ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Adhesion ◽  
Small Cell Lung Cancer ◽  
Adhesion Molecule ◽  
Cell Lung Cancer ◽  
Cell Adhesion Molecule ◽  
Neural Cell Adhesion Molecule ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neural Cell Adhesion

scholarly journals Interplay between Platelet Endothelial Cell Adhesion Molecule-1 and Pigment Epithelium-Derived Factor in Non-Small-Cell-Lung Cancer

2016 ◽  
Vol 06 (04) ◽  
pp. 47-56
Author(s):  
Alexander Emmert ◽  
Angelika Oellerich ◽  
Laszlo Füzesi ◽  
Regina Waldmann- Beushausen ◽  
Friedrich A. Schöndube ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Endothelial Cell ◽  
Cell Adhesion Molecule ◽  
Pigment Epithelium ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pigment Epithelium Derived Factor ◽  
Platelet Endothelial Cell Adhesion ◽  
Cell Adhesion Molecule 1 ◽  
Endothelial Cell Adhesion
Sign in / Sign up

Export Citation Format

Share Document